Pembrolizumab with Lenvatinib and chemotherapy for previously untreated advanced or metastatic gastroesophageal adenocarcinoma

Pembrolizumab in combination with lenvatinib and chemotherapy is in clinical development for patients with advanced or metastatic gastroesophageal adenocarcinoma. Gastric cancer (GC) also called stomach cancer, is cancer that starts in any part of the stomach or the stomach wall. Gastro-oesophageal junction cancer (GEJC) starts at the gastro-oesophageal junction, where the food pipe (oesophagus) joins the stomach. Advanced GC is cancer that started in the stomach and has spread to another part of the body. Some cancers do not respond or become unresponsive to treatment over time when a given drug is used as the sole treatment, hence the need for combinations of drugs that attack the tumour in different ways.